Who is affected by this change?

This affects Independence Blue Cross Hematology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective Apr 29, 2026.

Back to dashboard

CommercialCoverageLow impact

08.02.25a, Fidanacogene elaparvovec-dzkt (Beqvez™)

Independence Blue Cross·Hematology, Oncology·Pharmacy

Effective date

Apr 29, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a policy reissue for Fidanacogene elaparvovec-dzkt (Beqvez™), a gene therapy medication. The policy is being reissued with an effective date of April 29, 2026, indicating updated coverage or billing guidelines for this specialized pharmaceutical product.

Action Required

Action needed

By April 29, 2026: Billing team should review the full policy text at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Fidanacogene elaparvovec-dzkt (Beqvez™). Update billing systems and prior authorization workflows as needed once full policy details are available.

Related policy hubs

Independence Blue Cross policies Hematology Oncology